Exscientia (EXAI.US) was acquired by Nvidia's (NVDA.US) investment in Recursion (RXRX.US), causing a 16% surge in the share price.
AInvestThursday, Aug 8, 2024 9:50 am ET
1min read
EXAI --
NVDA --
RXRX --

Recursion Pharmaceuticals(RXRX.US), a drug development company powered by artificial intelligence, has agreed to buy smaller rival Exscientia(EXAI.US) in a $688m all-stock deal. Recursion, backed by chipmaker Nvidia(NVDA.US), uses AI to help develop new drugs. At the time of writing, Exscientia was up 16 per cent and Recursion was up 2 per cent.

Under the terms of the deal, Exscientia shareholders will receive 0.7729 shares of Recursion A class common stock for every share of common stock they hold. Some of the shares will be paid in cash.

The deal is expected to close in early 2025 and provide about $850m in cash for the merged entity to fund its operations over the next three years. Recursion shareholders will own about 74 per cent of the combined company, with Exscientia shareholders owning the rest.

The combined Recursion will be led by co-founder and chief executive Chris Gibson, while Exscientia’s interim chief executive David Hallett will become chief scientific officer.

In July, Recursion raised $50m from Nvidia, a boost for AI-driven biopharma stocks. Its peers Abcellera Biologics(ABCL.US), Absci Corporation(ABSI.US), Exscientia and Schrodinger(SDGR.US) all rallied.

Earlier this year, the company also unveiled a Nvidia supercomputer called BioHive-2, which helps speed up the drug discovery process.

Big pharma companies are increasingly using AI to speed up drug development, hoping to find trial patients more quickly or reduce the number of people needed to test drugs, which could both help speed up the drug development process and save, or even millions of dollars.

Najat Khan, chief research officer at Recursion, said: “The way we use end-to-end AI to go from biology to chemistry in drug discovery is very synergistic. That will allow us to make drugs faster and better, which is what we are trying to do.”

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.